Yuying Kou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuying Kou has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Minqi Li
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China
7 shared publications Hongrui Liu
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China
3 shared publicationsShanshan Liu
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University and Shandong Key Laboratory of Oral Tissue Regeneration and Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan 250100, China
3 shared publicationsXing Rong
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China
3 shared publications- Yupu Lu
Department of Bone Metabolism School and Hospital of Stomatology Cheeloo College of Medicine Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration Jinan China
3 shared publications - Hongrui Liu
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Cell Death Discovery
Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis
Glucocorticoid-induced osteoporosis (GIOP) is characterized by progressive cortical bone fragility accompanied by osteocyte lacunar enlargement and peri-lacunar osteolysis. However, whether these microstructural alterations arise from a specific cell death program remains unclear. Here, we demonstrate that glucocorticoids activate STIM1-ORAI1-dependent store-operated calcium entry (SOCE) in osteocytes, thereby promoting NFATc1 nuclear translocation. Activated NFATc1 induces mitophagy arrest, accumulation of dysfunctional mitochondria, and a burst of mitochondrial reactive oxygen species (mtROS), which subsequently triggers RIPK1/RIPK3/MLKL-mediated necroptosis. In a murine GIOP model, pharmacological inhibition of SOCE and NFATc1 knockdown each abrogated osteocyte necroptosis, alleviated cortical osteolysis, and preserved bone mechanical properties. Osteocyte-specific deletion of MLKL phenocopied these protective effects, further confirming necroptosis as the terminal effector of this process. Collectively, these findings identify the SOCE–NFATc1–mitophagy–mtROS axis as a critical signaling pathway linking calcium dysregulation to oxidative injury in osteocytes. Targeting this pathway disrupts the redox vulnerability underlying glucocorticoid-induced cortical bone loss and provides a therapeutic strategy for preserving skeletal integrity during long-term glucocorticoid therapy.
- 21 September 2026
- Published by Springer Nature in Cell Death Discovery
Open AccessOsteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis
Glucocorticoid-induced osteoporosis (GIOP) is characterized by progressive cortical bone fragility accompanied by osteocyte lacunar enlargement and peri-lacunar osteolysis. However, whether these microstructural alterations arise from a specific cell death program remains unclear. Here, we demonstrate that glucocorticoids activate STIM1-ORAI1-dependent store-operated calcium entry (SOCE) in osteocytes, thereby promoting NFATc1 nuclear translocation. Activated NFATc1 induces mitophagy arrest, accumulation of dysfunctional mitochondria, and a burst of mitochondrial reactive oxygen species (mtROS), which subsequently triggers RIPK1/RIPK3/MLKL-mediated necroptosis. In a murine GIOP model, pharmacological inhibition of SOCE and NFATc1 knockdown each abrogated osteocyte necroptosis, alleviated cortical osteolysis, and preserved bone mechanical properties. Osteocyte-specific deletion of MLKL phenocopied these protective effects, further confirming necroptosis as the terminal effector of this process. Collectively, these findings identify the SOCE–NFATc1–mitophagy–mtROS axis as a critical signaling pathway linking calcium dysregulation to oxidative injury in osteocytes. Targeting this pathway disrupts the redox vulnerability underlying glucocorticoid-induced cortical bone loss and provides a therapeutic strategy for preserving skeletal integrity during long-term glucocorticoid therapy.
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 11525-11545
Vitamin K2 Protects Against Glucocorticoid-Induced Osteoporosis by Activating the NRF2/FSP1 Pathway to Inhibit Osteoblast Ferroptosis
Purpose: Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and its pathogenesis is closely associated with oxidative stress and impaired osteogenic differentiation. Vitamin K2 (VK2) has strong antioxidant properties and potent bone-forming effects, but its application in GIOP is still unclear. This study investigates the therapeutic potential of VK2 in GIOP and elucidates its underlying molecular mechanisms. Methods: Dexamethasone (DEX) was used to establish GIOP model within C57BL/6 mice. The bone mass was assessed using micro-computed tomography (micro-CT), hematoxylin and eosin (HE) staining, and Masson’s trichrome staining in vivo. The osteoblast activity and the expression of osteogenic and ferroptosis-related markers were evaluated via immunohistochemistry (IHC), RT-qPCR, Western blotting, ALP and alizarin red staining. The mitochondrial function and lipid peroxidation of MC3T3-E1 cells were detected by flow cytometry, immunofluorescence and specific kits. Results: VK2 partially prevented bone mass reduction and osteoblast activity inhibition in GIOP mice. VK2 not only reversed the DEX-induced reductions in Tb.N, BV/TV, and Tb.Th, but also significantly increased the expression of osteogenic markers, including OCN and ALP (P< 0.05). Moreover, VK2 improved DEX-induced ferroptosis, oxidative stress and mitochondrial dysfunction in MC3T3-E1 cells and promoted osteogenic differentiation in vitro, which could be reversed by ferroptosis inducer (P< 0.05). VK2 also increased the expression of NRF2, HO-1 and FSP1 which inhibited by DEX in vivo and in vitro (P< 0.05). The inhibition of FSP1 and NRF2 reversed the osteogenic differentiation promotion and ferroptosis inhibition by VK2 (P< 0.05). Conclusion: VK2 restores mitochondrial function and reduces lipid peroxidation and ferroptosis via the NRF2/FSP1 signaling pathway, thereby facilitating osteoblast differentiation and improving bone mass in GIOP mice. This finding not only provides a fresh perspective on the etiology of GIOP but also positions ferroptosis inhibition as a promising and innovative therapeutic strategy for this condition, with VK2 emerging as a potential candidate for clinical translation.
- 1 December 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 11525-11545
Open AccessVitamin K2 Protects Against Glucocorticoid-Induced Osteoporosis by Activating the NRF2/FSP1 Pathway to Inhibit Osteoblast Ferroptosis
Purpose: Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and its pathogenesis is closely associated with oxidative stress and impaired osteogenic differentiation. Vitamin K2 (VK2) has strong antioxidant properties and potent bone-forming effects, but its application in GIOP is still unclear. This study investigates the therapeutic potential of VK2 in GIOP and elucidates its underlying molecular mechanisms. Methods: Dexamethasone (DEX) was used to establish GIOP model within C57BL/6 mice. The bone mass was assessed using micro-computed tomography (micro-CT), hematoxylin and eosin (HE) staining, and Masson’s trichrome staining in vivo. The osteoblast activity and the expression of osteogenic and ferroptosis-related markers were evaluated via immunohistochemistry (IHC), RT-qPCR, Western blotting, ALP and alizarin red staining. The mitochondrial function and lipid peroxidation of MC3T3-E1 cells were detected by flow cytometry, immunofluorescence and specific kits. Results: VK2 partially prevented bone mass reduction and osteoblast activity inhibition in GIOP mice. VK2 not only reversed the DEX-induced reductions in Tb.N, BV/TV, and Tb.Th, but also significantly increased the expression of osteogenic markers, including OCN and ALP (P< 0.05). Moreover, VK2 improved DEX-induced ferroptosis, oxidative stress and mitochondrial dysfunction in MC3T3-E1 cells and promoted osteogenic differentiation in vitro, which could be reversed by ferroptosis inducer (P< 0.05). VK2 also increased the expression of NRF2, HO-1 and FSP1 which inhibited by DEX in vivo and in vitro (P< 0.05). The inhibition of FSP1 and NRF2 reversed the osteogenic differentiation promotion and ferroptosis inhibition by VK2 (P< 0.05). Conclusion: VK2 restores mitochondrial function and reduces lipid peroxidation and ferroptosis via the NRF2/FSP1 signaling pathway, thereby facilitating osteoblast differentiation and improving bone mass in GIOP mice. This finding not only provides a fresh perspective on the etiology of GIOP but also positions ferroptosis inhibition as a promising and innovative therapeutic strategy for this condition, with VK2 emerging as a potential candidate for clinical translation.
- Open Access
- 1 May 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 1515-1528
ED-71 Improves Bone Mass in Ovariectomized Rats by Inhibiting Osteoclastogenesis Through EphrinB2-EphB4-RANKL/OPG Axis
Purpose: Estrogen deficiency is the main reason of postmenopausal osteoporosis. Eldecalcitol (ED-71) is a new active vitamin D analogue clinically used in the treatment of postmenopausal osteoporosis. We aimed to investigate whether EphrinB2-EphB4 and RANKL/RANK/OPG signaling cooperate in mediating the process of osteoporosis by ED-71. Methods: In vivo, the ovariectomized (OVX) rats were administered orally with 30 ng/kg ED-71 once a day for 8 weeks. HE staining, Masson staining and Immunofluorescence staining were used to evaluate bone mass, bone formation, osteoclastogenesis associated factors and the expression of EphrinB2, EphB4, RANKL and OPG. In vitro, H2O2 stimulation was used to simulate the cell environment in osteoporosis. Immunofluorescence, quantitative real time PCR (qRT-PCR), enzyme-linked immunosorbent assay (ELISA) and Western Blot were applied to detect the expression of EphrinB2, EphB4, RANKL and OPG. In osteoblasts, EphB4 was knocked down by EphB4 small-interfering RNA (siRNA) transfection. LY294002 (PI3K inhibitor) or ARQ092 (AKT inhibitor) was used to block PI3K/AKT pathway. An indirect co-culture system of osteoblasts and osteoclasts was established. The mRNA and protein expression of osteoclastogenes is associated factors were tested by qRT-PCR and Western Blot. Results: ED-71 increased bone mass and decreased the number of osteoclasts in OVX rats. Moreover, ED-71 promoted the expression of EphrinB2, EphB4, and decreased the RANKL/OPG ratio in osteoblasts. Osteoclastogenesis was restrained when osteoclasts were indirectly co-cultured with ED-71-treated osteoblasts. After silencing of EphB4 expression in osteoblasts, ED-71 inhibited the expression of P-PI3K and P-AKT and increased the ratio of RANKL/OPG. This reversed the inhibitory effect of ED-71 on osteoclastogenes. Therefore, in ED-71-inhibited osteoclastogenes, EphB4 is a key factor affecting the secretion of RANKL and OPG by osteoblasts. EphB4 suppressed the RANKL/OPG ratio through activating PI3K/AKT signaling in osteoblasts. Conclusion: ED-71 inhibits osteoclastogenesis through EphrinB2-EphB4-RANKL/OPG axis, improving bone mass in ovariectomized rats. PI3K/AKT pathway is involved this process.
- 1 May 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 1515-1528
Open AccessED-71 Improves Bone Mass in Ovariectomized Rats by Inhibiting Osteoclastogenesis Through EphrinB2-EphB4-RANKL/OPG Axis
Purpose: Estrogen deficiency is the main reason of postmenopausal osteoporosis. Eldecalcitol (ED-71) is a new active vitamin D analogue clinically used in the treatment of postmenopausal osteoporosis. We aimed to investigate whether EphrinB2-EphB4 and RANKL/RANK/OPG signaling cooperate in mediating the process of osteoporosis by ED-71. Methods: In vivo, the ovariectomized (OVX) rats were administered orally with 30 ng/kg ED-71 once a day for 8 weeks. HE staining, Masson staining and Immunofluorescence staining were used to evaluate bone mass, bone formation, osteoclastogenesis associated factors and the expression of EphrinB2, EphB4, RANKL and OPG. In vitro, H2O2 stimulation was used to simulate the cell environment in osteoporosis. Immunofluorescence, quantitative real time PCR (qRT-PCR), enzyme-linked immunosorbent assay (ELISA) and Western Blot were applied to detect the expression of EphrinB2, EphB4, RANKL and OPG. In osteoblasts, EphB4 was knocked down by EphB4 small-interfering RNA (siRNA) transfection. LY294002 (PI3K inhibitor) or ARQ092 (AKT inhibitor) was used to block PI3K/AKT pathway. An indirect co-culture system of osteoblasts and osteoclasts was established. The mRNA and protein expression of osteoclastogenes is associated factors were tested by qRT-PCR and Western Blot. Results: ED-71 increased bone mass and decreased the number of osteoclasts in OVX rats. Moreover, ED-71 promoted the expression of EphrinB2, EphB4, and decreased the RANKL/OPG ratio in osteoblasts. Osteoclastogenesis was restrained when osteoclasts were indirectly co-cultured with ED-71-treated osteoblasts. After silencing of EphB4 expression in osteoblasts, ED-71 inhibited the expression of P-PI3K and P-AKT and increased the ratio of RANKL/OPG. This reversed the inhibitory effect of ED-71 on osteoclastogenes. Therefore, in ED-71-inhibited osteoclastogenes, EphB4 is a key factor affecting the secretion of RANKL and OPG by osteoblasts. EphB4 suppressed the RANKL/OPG ratio through activating PI3K/AKT signaling in osteoblasts. Conclusion: ED-71 inhibits osteoclastogenesis through EphrinB2-EphB4-RANKL/OPG axis, improving bone mass in ovariectomized rats. PI3K/AKT pathway is involved this process.
- Open Access
- 26 October 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (44) , 39760-39771
ATP Promotes Oral Squamous Cell Carcinoma Cell Invasion and Migration by Activating the PI3K/AKT Pathway via the P2Y2-Src-EGFR Axis
Oral cancer is one of the most common malignancies of the head and neck, and approximately 90% of oral cancers are oral squamous cell carcinomas (OSCCs). The purinergic P2Y2 receptor is upregulated in breast cancer, pancreatic cancer, colorectal cancer, and liver cancer, but its role in OSCC is still unclear. Here, we examined the effects of P2Y2 on the invasion and migration of oral cancer cells (SCC15 and CAL27). The BALB/c mouse model was used to observe the involvement of P2Y2 with tumors in vivo. P2Y2, Src, and EGFR are highly expressed in OSCC tissues and cell lines. Stimulation with ATP significantly enhanced cell invasion and migration in oral cancer cells, and enhanced the activity of Src and EGFR protein kinases, which is mediated by the PI3K/AKT signaling pathway. P2Y2 knockdown attenuated the above ATP-driven events in vitro and in vivo. The PI3K/ AKT signaling pathway was blocked by Src or EGFR inhibitor. Extracellular ATP activates the PI3K/AKT pathway through the P2Y2-Src-EGFR axis to promote OSCC invasion and migration, and thus, P2Y2 may be a potential novel target for antimetastasis therapy.
- 26 October 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (44) , 39760-39771
Open AccessATP Promotes Oral Squamous Cell Carcinoma Cell Invasion and Migration by Activating the PI3K/AKT Pathway via the P2Y2-Src-EGFR Axis
Oral cancer is one of the most common malignancies of the head and neck, and approximately 90% of oral cancers are oral squamous cell carcinomas (OSCCs). The purinergic P2Y2 receptor is upregulated in breast cancer, pancreatic cancer, colorectal cancer, and liver cancer, but its role in OSCC is still unclear. Here, we examined the effects of P2Y2 on the invasion and migration of oral cancer cells (SCC15 and CAL27). The BALB/c mouse model was used to observe the involvement of P2Y2 with tumors in vivo. P2Y2, Src, and EGFR are highly expressed in OSCC tissues and cell lines. Stimulation with ATP significantly enhanced cell invasion and migration in oral cancer cells, and enhanced the activity of Src and EGFR protein kinases, which is mediated by the PI3K/AKT signaling pathway. P2Y2 knockdown attenuated the above ATP-driven events in vitro and in vivo. The PI3K/ AKT signaling pathway was blocked by Src or EGFR inhibitor. Extracellular ATP activates the PI3K/AKT pathway through the P2Y2-Src-EGFR axis to promote OSCC invasion and migration, and thus, P2Y2 may be a potential novel target for antimetastasis therapy.
- 22 March 2022
- Published by Wiley in Oral Diseases
- Vol. 29 (5) , 2188-2204
Periostin regulates LPS‐induced apoptosis via Nrf2/HO‐1 pathway in periodontal ligament fibroblasts
Objective: Periostin is important for the maintenance of periodontal tissue, but its role in periodontitis is controversial. This research investigated the effect of periostin in periodontitis and the underlying mechanism.Design: Mouse periodontitis models in vivo and inflammation model in vitro which were induced by Porphyromonas gingivalis lipopolysaccharide were established to evaluate periostin expression. Human periodontal ligament fibroblasts (PDLFs) were treated with lipopolysaccharide and N‐acetylcysteine, fluorescence staining, flow cytometry, Western blot, and qRT‐PCR were used to detect reactive oxygen species (ROS), periostin expression, and apoptosis‐related makers. The periostin gene was successfully transfected into PDLFs to verify the effect of periostin on apoptosis. Then, the Nrf2 inhibitor was added to clarify the mechanism.Results: Periostin expression decreased in the periodontal ligaments of mouse periodontitis models and lipopolysaccharide‐induced PDLFs. Lipopolysaccharide promoted the activation of ROS and apoptosis in PDLFs, whereas N‐acetylcysteine reversed this condition. Overexpression of periostin suppressed apoptosis of PDLFs and reversed the inhibitory effect of lipopolysaccharide on nuclear Nrf2 expression. Moreover, the Nrf2 inhibitor attenuated the protective effect of periostin on lipopolysaccharide‐induced apoptosis.Conclusions: Lipopolysaccharide induced apoptosis in PDLFs by inhibiting periostin expression and thus Nrf2/HO‐1 pathway, indicating that periostin could be a potential therapeutic target for periodontitis.
- 22 March 2022
- Published by Wiley in Oral Diseases
- Vol. 29 (5) , 2188-2204
Periostin regulates LPS‐induced apoptosis via Nrf2/HO‐1 pathway in periodontal ligament fibroblasts
Objective: Periostin is important for the maintenance of periodontal tissue, but its role in periodontitis is controversial. This research investigated the effect of periostin in periodontitis and the underlying mechanism.Design: Mouse periodontitis models in vivo and inflammation model in vitro which were induced by Porphyromonas gingivalis lipopolysaccharide were established to evaluate periostin expression. Human periodontal ligament fibroblasts (PDLFs) were treated with lipopolysaccharide and N‐acetylcysteine, fluorescence staining, flow cytometry, Western blot, and qRT‐PCR were used to detect reactive oxygen species (ROS), periostin expression, and apoptosis‐related makers. The periostin gene was successfully transfected into PDLFs to verify the effect of periostin on apoptosis. Then, the Nrf2 inhibitor was added to clarify the mechanism.Results: Periostin expression decreased in the periodontal ligaments of mouse periodontitis models and lipopolysaccharide‐induced PDLFs. Lipopolysaccharide promoted the activation of ROS and apoptosis in PDLFs, whereas N‐acetylcysteine reversed this condition. Overexpression of periostin suppressed apoptosis of PDLFs and reversed the inhibitory effect of lipopolysaccharide on nuclear Nrf2 expression. Moreover, the Nrf2 inhibitor attenuated the protective effect of periostin on lipopolysaccharide‐induced apoptosis.Conclusions: Lipopolysaccharide induced apoptosis in PDLFs by inhibiting periostin expression and thus Nrf2/HO‐1 pathway, indicating that periostin could be a potential therapeutic target for periodontitis.
- 5 November 2021
- Published by Wiley in Oral Diseases
- Vol. 29 (3) , 1149-1162
Regulatory T cells showed characteristics of T helper‐17(Th17) cells in mice periodontitis model
Objectives: This study aimed to clarify the regulatory role of Th17‐Treg balance in periodontitis and further reveal Treg plasticity.Materials and Methods: An experimental periodontitis model was established by ligation and injection of Pg‐LPS. Inflammatory factors were measured by ELISA and RT‐PCR. Alveolar bone absorption was evaluated by micro‐CT and histomorphology. Quantities of Treg and Th17 cell and their related gene expression were examined. Furthermore, after magnetic bead‐sorting spleen Treg cells, Treg/Th17 characteristic genes were explored. Immunofluorescence double staining of Foxp3 and IL‐17 was conducted to further reveal Treg plasticity.Results: Inflammatory cytokines in serum and gingival tissue increased significantly in periodontitis, which revealed obvious crestal bone loss. Further analysis showed that the number of Th17 cells and expression of related genes increased more significantly than Treg cells, demonstrating Treg‐Th17 imbalance. Flow cytometry showed that the proportions of Treg cells in the blood and spleen were lower in periodontitis group. Furthermore, Foxp3 was downregulated, and Rorc/ IL‐17A were increased in Treg cells of periodontitis group. Immunofluorescence double staining showed significantly increased number of IL‐17+Foxp3+ cells in periodontitis.Conclusions: These results provided evidence that Treg cells showed characteristics of Th17 cells in mice with periodontitis, although its mechanisms require further study.
- 5 November 2021
- Published by Wiley in Oral Diseases
- Vol. 29 (3) , 1149-1162
Regulatory T cells showed characteristics of T helper‐17(Th17) cells in mice periodontitis model
Objectives: This study aimed to clarify the regulatory role of Th17‐Treg balance in periodontitis and further reveal Treg plasticity.Materials and Methods: An experimental periodontitis model was established by ligation and injection of Pg‐LPS. Inflammatory factors were measured by ELISA and RT‐PCR. Alveolar bone absorption was evaluated by micro‐CT and histomorphology. Quantities of Treg and Th17 cell and their related gene expression were examined. Furthermore, after magnetic bead‐sorting spleen Treg cells, Treg/Th17 characteristic genes were explored. Immunofluorescence double staining of Foxp3 and IL‐17 was conducted to further reveal Treg plasticity.Results: Inflammatory cytokines in serum and gingival tissue increased significantly in periodontitis, which revealed obvious crestal bone loss. Further analysis showed that the number of Th17 cells and expression of related genes increased more significantly than Treg cells, demonstrating Treg‐Th17 imbalance. Flow cytometry showed that the proportions of Treg cells in the blood and spleen were lower in periodontitis group. Furthermore, Foxp3 was downregulated, and Rorc/ IL‐17A were increased in Treg cells of periodontitis group. Immunofluorescence double staining showed significantly increased number of IL‐17+Foxp3+ cells in periodontitis.Conclusions: These results provided evidence that Treg cells showed characteristics of Th17 cells in mice with periodontitis, although its mechanisms require further study.
- 24 August 2021
- Published by Wiley in Oral Diseases
- Vol. 29 (2) , 615-627
Eldecalcitol inhibits the progression of oral cancer by suppressing the expression of GPx‐1
Objectives: This study aimed to investigate the role of eldecalcitol in the progression of oral squamous cell carcinoma and to explore the related mechanism.Materials and Methods: The effects of eldecalcitol on the proliferation, cell cycle, apoptosis, and migration of oral cancer cells (SCC‐15 and CAL‐27) were evaluated with cell counting kit‐8, flow cytometry, quantitative real‐time polymerase chain reaction, western blotting, and scratch assay. Mouse xenograft tumor model was established to further confirm the role of eldecalcitol in the progression of oral cancer. Immunohistochemistry, quantitative real‐time polymerase chain reaction, and western blotting were used to detect glutathione peroxidase‐1 expression in oral cancer tissue and cells treated with eldecalcitol.Results: Eldecalcitol was found to inhibit the proliferation and migration of SCC‐15 and CAL‐27 cells significantly, block the cell cycle in the G0/G1 phase, and enhance the apoptosis. In addition, glutathione peroxidase‐1 was downregulated by eldecalcitol and acted as an important medium of eldecalcitol in inhibiting the proliferation and migration of SCC‐15 and CAL‐27 cells, as well as promoting their apoptosis.Conclusions: Eldecalcitol may inhibit the progression of oral cancer by suppressing the expression of glutathione peroxidase‐1, which may provide new insight into the application of eldecalcitol as a potential anti‐cancer drug.
- 24 August 2021
- Published by Wiley in Oral Diseases
- Vol. 29 (2) , 615-627
Eldecalcitol inhibits the progression of oral cancer by suppressing the expression of GPx‐1
Objectives: This study aimed to investigate the role of eldecalcitol in the progression of oral squamous cell carcinoma and to explore the related mechanism.Materials and Methods: The effects of eldecalcitol on the proliferation, cell cycle, apoptosis, and migration of oral cancer cells (SCC‐15 and CAL‐27) were evaluated with cell counting kit‐8, flow cytometry, quantitative real‐time polymerase chain reaction, western blotting, and scratch assay. Mouse xenograft tumor model was established to further confirm the role of eldecalcitol in the progression of oral cancer. Immunohistochemistry, quantitative real‐time polymerase chain reaction, and western blotting were used to detect glutathione peroxidase‐1 expression in oral cancer tissue and cells treated with eldecalcitol.Results: Eldecalcitol was found to inhibit the proliferation and migration of SCC‐15 and CAL‐27 cells significantly, block the cell cycle in the G0/G1 phase, and enhance the apoptosis. In addition, glutathione peroxidase‐1 was downregulated by eldecalcitol and acted as an important medium of eldecalcitol in inhibiting the proliferation and migration of SCC‐15 and CAL‐27 cells, as well as promoting their apoptosis.Conclusions: Eldecalcitol may inhibit the progression of oral cancer by suppressing the expression of glutathione peroxidase‐1, which may provide new insight into the application of eldecalcitol as a potential anti‐cancer drug.